Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms

Cancer

Volumn 106, Issue 12, 2006, Pages 2592-2597

  Kebebew, Electron ^a,b   Peng, Miao ^b   Reiff, Emily ^b   McMillan, Alex ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnostic markers; Prognostic markers; Quantitative polymerase chain reaction; Thyroid cancer

Indexed keywords

ANGIOPOIETIN 2; EPHRIN B2; EPIDERMAL GROWTH FACTOR RECEPTOR; EXTRACELLULAR MATRIX PROTEIN 1; GENE PRODUCT; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSMEMBRANE PROTEASE SERINE 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGPT2 GENE; ARTICLE; ASPIRATION BIOPSY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECM1 GENE; GENE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE; TIMP1 GENE; TMPRSS4 GENE;

ANGIOPOIETIN-2; BIOPSY, FINE-NEEDLE; DATA INTERPRETATION, STATISTICAL; DIAGNOSIS, DIFFERENTIAL; EPHRIN-B2; EXTRACELLULAR MATRIX PROTEINS; GENES, NEOPLASM; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; THYROID DISEASES; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 33745186955     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21922     Document Type: Article

References (27)

1. Greaves TS, Olvera M, Florentine BD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer (Cancer Cytopathol). 2000;90:335-341.
2. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44.
3. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282-289.
4. Cersosimo E, Gharib H, Suman VJ, Goellner JR. "Suspicious" thyroid cytologic findings: outcome in patients without immediate surgical treatment. Mayo Clin Proc. 1993;68:343-348.
5. Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med. 1993;13:699-709.
6. Hooft L, Hoekstra OS, Boers M, Van Tulder MW, Van Diest P, Lips P. Practice, efficacy, and costs of thyroid nodule evaluation: a retrospective study in a Dutch university hospital. Thyroid. 2004;14:287-293.
7. Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid. 1998; 8:377-383.
8. Basu D, Jayaram G. A logistic model for thyroid lesions. Diagn Cytopathol 1992;8:23-27.
9. Eldar S, Sabo E, Cohen A, et al. The value of histomorphometric nuclear parameters in the diagnosis of well differentiated follicular carcinomas and follicular adenomas of the thyroid gland. Histopathology. 1999;34:453-461.
10. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery. 1994;116:1054-1060.
11. Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg. 2000;24:942-951.
12. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 1997;79:2414-2423.
13. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133:419-425.
14. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229-239.
15. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
16. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann Surg. 2005;242:353-361; discussion 361-353.
17. Kebebew E, Peng M, McMillan A, Clark OH, Duh QY, Reiff E. Diagnostic and prognostic value of angiogenesis regulatory genes in malignant thyroid neoplasms. Surgery. 2005;138: 1102-1109.
18. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30:503-512.
19. Baloch ZW, LiVolsi VA. The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. Am J Clin Pathol. 2002;118:165-166.
20. National Cancer Institute. Surveillance, Epidemiology, and End Results, Cancer Statistics Review, 1975-2001. Available at URL: http://seer.cancer.gov/ csr/1975_2001/results_merged/sect_25_thyroid.pdf [accessed on January 23, 2005].
21. Silver RJ, Parangi S. Management of thyroid incidentalomas. Surg Clin North Am. 2004;84:907-919.
22. Supit E, Peiris AN. Cost-effective management of thyroid nodules and nodular thyroid goiters. South Med J. 2002;95: 514-519.
23. Caplan RH, Wester SM, Lambert PJ, Rooney BL. Efficient evaluation of thyroid nodules by primary care providers and thyroid specialists. Am J Manag Care. 2000;6:1134-1140.
24. Bojunga J, Zeuzem S. Molecular detection of thyroid cancer: an update. Clin Endocrinol (Oxf). 2004;61:523-530.
25. Rosai J. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori. 2003;89: 517-519.
26. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer. 2004;40:2753-2759.
27. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.